缺血性中风后尿微量蛋白的增加与高血压的阶段，血清脂质水平和脂质代谢障碍的类型有关。
Urine microproteins increasing in ischemic apoplexy are relative to stages of hypertension, serum lipid level and types of lipid dysbolism.
方法用酶联免疫吸附法测定尿微量蛋白。
Methods Using Enzyme Immunosorbent Assay detected urine micro protein.
目的观察不同妊娠期对正常孕妇尿微量蛋白质的影响。
Objective To investigate the effect of pregnancy time on urinary micro protein in normal pregnancy women.
目的观察红花注射液对早期高血压肾病尿微量蛋白的影响。
Objective To investigate the effects of safflower injection on uromicroprotein of early stage hypertensive nephropathy.
目的：探讨尿微量蛋白水平检测对老年高血压肾损害的早期诊断价值。
Objective: To study the diagnostic value of renal trace protein test on early kidney lesion in aged patients with hypertension.
结果：治疗组血流变学、24小时尿微量蛋白定量疗效明显优于对照组。
Results:The groups of treatment on effect were obervious better than contrast groups in bloodflow change and mivroprotein in 24 hours urine.
尿微量蛋白检测为诊断早期肾损害的灵敏指标，可判断肾损害的部位及程度；
The test of urinary micro protein is a sensitive indication for diagnosis of early renal impairment. The renal impairment position and degree could be evaluated by the test.
而高血压早期肾脏就出现了以尿微量蛋白等为特征的肾小管肾小球的功能异常。
And the disfunctions of nephric tubule and glomerulus characterized by renal small protein have appeared in the earlier period of the hypertensive kidney.
目的探讨老年2型糖尿病（DM）尿微量蛋白与颈部血管动脉粥样硬化的关系。
Objective To evaluate the relationship between carotid arterial atherosclerosis and microproteinuria in elderly type 2 diabetes mellitus(DM) patients.
探讨尿微量蛋白及补体在系统性红斑狼疮（SLE）肾功能损伤诊断中的临床价值。
To observe the clinical value of urinary slight albumin and alexin in diagnosing kidney function injury of on Systemic Erythema Lupus(SLE).
结论缺血性中风尿微量蛋白增高与高血压分期、血脂水平及脂质代谢障碍的类型有关；
Conclusion Urine microproteins increasing in ischemic apoplexy is relative to stages of hypertension, serum lipid level and types of lipid dysbolism.
测定尿微量蛋白对诊断颅脑伤患者早期肾脏功能损害有重要临床应用价值，而尿ggt的临床应用价值则不理想。
Uromicroprotein is an important clinical index for the diagnosis of early kidney lesion in patients with brain injury, but GGT is not ideal for the clinical application.
目的探讨早期糖尿病肾病（DN）肾小球滤过率（GFR）和肾有效血浆流量（ERPF）与尿微量蛋白的变化特点及其相互关系。
Objective To evaluate the changes of glomerular filtration rate (GFR), effective renal plasma flow (ERPF) and microalbuminuria in early diabetic nephropathy (DN) and their correlation.
结论：奥美沙坦与微量蛋白尿延缓出现有关，尽管基于现行标准，两组患者的血压控制情况均较好。
CONCLUSIONS: Olmesartan was associated with a delayed onset of microalbuminuria, even though blood-pressure control in both groups was excellent according to current standards.
所以我们是在病人中观察新发生的微量白蛋白尿。
So we were looking at the developments of new microalbuminuria in these patients.
对患有微量白蛋白尿的2型糖尿病患者的深度多因素临床干预几乎阻止了糖尿病蛋白尿的进展，但却能改变GF R减低的结局。
Intensive multifactorial intervention in patients with type 2 diabetes with microalbuminuria nearly halved the progression of proteinuria but did not alter the rate of GFR decline.
此外，ROADMAP数据证明奥美沙坦可预防2型糖尿病患者发生微量白蛋白尿(mau)。
In addition, data from ROADMAP proved that olmesartan can reduce risk of microalbuminuria (MAU) in Type 2 diabetes (T2DM) patients.
目的了解肥胖症患儿尿微量清蛋白(mau)的改变及其发生机制。
Objective To understand change and pathogenesis of microalbuminuria (MAU) in cases of adiposity.
目的观察在微量白蛋白尿发生前后应用氯沙坦对糖尿病肾病(DN)的治疗作用及其机制。
Objective To estimate the therapeutical effect and mechanism of losartan on diabetic nephropathy (DN) before and after microalbuminuria.
目的探讨微量白蛋白尿(MA)与非糖尿病急性心肌梗死(NDM AMI)患者预后的关系。
Objective To investigate prognostic significance of microalbuminuria (MA) in non-diabetic acute myocardial infarction (NDM-AMI) patients.
微量白蛋白尿组发生联合终点事件的机率较正常UACR组高43%。
Patients with microalbuminuria were 43 percent more likely to reach the combined end point than those with normal UACR.
结论普伐他汀可改善代谢综合征患者的血脂紊乱、高血压及微量白蛋白尿，可安全地应用于代谢综合征患者。
Conclusion Pravastatin can be safely used for treating metabolic syndrome because it can ameliorate the lipid disturbance, hypertension and microalbuminuria.
结论微量白蛋白尿的测定可用于监测、防治糖尿病性心脏病。
Conclusions The menstruations of micro albumin urine can be applied to the prevention of diabetic heart disease.
目的观察低分子蛋白尿对2型糖尿病微量蛋白尿患者进展到临床糖尿病肾病的预后判断作用。
Objective To investigate the predictive value of urinary low molecular weight proteins for progression of diabetic nephropathy in type 2 diabetic patient with microalbuminuria.
目的研究急性脑梗死患者微量白蛋白尿(mau)的发生率、与卒中危险因素及脑梗死复发的关系。
Objective to assess the prevalence of microalbuminuria (MAU) in patients with recent cerebral infarction and its associations to risk factors for stroke and recurrence.
微量白蛋白尿和DR患者GFR下降最快。
Patients with microalbuminuria and DR showed the fastest GFR decline.
如果你发现在没有微量蛋白尿或巨量蛋白尿的情况下，GFR估计值在60以下，那么这个公式就是无效的，患者的风险并没有升高。
It is still valid but if you find someone with an estimated GFR below 60 without microalbuminuria or macroalbuminuria then the story is that the risk for this patient is not elevated.
结论中药护肾胶囊可明显减少尿微量白蛋白排泄率，改善高血脂、高血黏滞状态，保护肾功能。
Conclusion Hushen capsule could reduce notably excretory rate of urine trace albumin, which could improve the blood viscosity, hyperlipidemia and renal function.
我们研究了使用血管紧张素受体阻断剂（ARB）进行治疗是否能延缓或预防尿白蛋白正常的2型糖尿病患者出现微量蛋白尿。
We investigated whether treatment with an angiotensin-receptor blocker (ARB) would delay or prevent the occurrence of microalbuminuria in patients with type 2 diabetes and normoalbuminuria.
本研究以糖尿病患者出现肾损害的最初临床表现——微量白蛋白尿的出现比率作为标准，进行各组间的比较。
Rates of microalbuminuria-small amounts of the protein albumin in urine, the first sign of diabetic kidney disease-were compared between groups.
应用推荐